drugset / Trial / NCT03438955
Phase I Drug-drug Interaction of Omega-3 and Atorvastatin
Non-randomizedParallel-groupOpen-labelOther
Summary
This study evaluates the safety and pharmacokinetic drug-drug interactions of omega-3 and atorvastatin in healthy male volunteers. Half of the participants will receive omega-3 for 16 days to be steady state of omega-3 and followed by omega-3 and atorvastatin in combination for 7 days. The other half will receive Atorvastatin for 7 days to be steady state of Atorvastatin, and followed by Atorvastatin and Omega-3 in combination for 16 days.
Timeline
- Start
- 2018-02-01
- Primary completion
- 2018-07-31
- Completion
- 2018-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lovaza | Other / unclassified | 4000 mg | Oral |
| Subject | Telmisartan | Other / unclassified | 40 mg | Oral |